MolMed coordinates a CAR T-cell immunotherapy project awarded a 5.9 million Euro grant by the European Commission

Milan (Italy), December 12, 2016 - MolMed S.p.A. is glad to announce that the European Commission, within the Horizon 2020 - Research and Innovation Framework Programme section reserved to the new therapies for chronic diseases (including cancer), has awarded a 5,903,146 Euro grant to the project called EURE-CART (EÜRopean Endeavour for Chimeric Antigen Receptor Therapies), of which MolMed is coordinator.

Adoptive immunotherapy with T cells genetically modified with a tumour-reactive CAR is an innovative therapeutic concept, promising to eradicate cancer cells, without causing secondary chronic diseases. The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating neoplastic diseases.

The grant will partially cover R&D expenses of the project over a 48-month period.

MolMed will receive Euro 1,994,575 out of the total amount granted and will coordinate the project; in addition, being uniquely endowed with the necessary know-how and experience, as demonstrated by its unparalleled track record, it will manufacture both research- and clinical-grade T cells genetically modified with CD44v6-CAR vector for use in cancer immunotherapy investigated by the project.

EURE-CART project’s main object is to conduct a multicentre, first-in-man Phase I/IIa clinical trial to demonstrate the safety and the efficacy of CD44v6 CAR T-cell immunotherapy in Acute Myeloid Leukaemia and Multiple Myeloma.

EURE-CART will involve a Consortium of nine different partners from 6 EU countries, including clinical, scientific and industrial groups, clearly representing excellences in their respective fields: MolMed S.p.A. (Italy) Ospedale San Raffaele srl (Italy), Universitätsklinikum Würzburg - Klinikum Der Bayerischen Julius-Maximilians-Universität (Germany), Ospedale Pediatrico Bambino Gesù (Italy), Fundacio Privada Institut de Recerca de L’Hospital de la Santa Creu i Sant Pau (Spain), Fakultní Nemocnice S Poliklinikou Ostrava Foundation (Czech Republic), Istituto Superiore di Sanità (Italy), Acromion GMBH (Germany), ARTTIC SAS (France). The project will thus rely on distinguished investigators, with proven and complementary scientific contributions in the areas of translational and clinical tumour immunotherapy and gene therapy: Dr. Catia Traversari – (MolMed S.p.A.); Prof. Dr. Attilio Bondanza MD, PhD (Ospedale San Raffaele S.r.l.), Prof. Dr. Hermann Einsele, MD (Universitätsklinikum Würzburg); Prof. Franco Locatelli MD (Ospedale Pediatrico Bambino Gesù); Prof., Jorge Sierra MD (Hospital de Sant Pau (Spain); Prof. Roman Hájek, MD PhD (University Hospital Ostrava); Dr. Maria Cristina Galli, PhD (Istituto Superiore di Sanità).

Claudio Bordignon, MolMed’s Chairman commented: “This significant grant that aims to bring EU at the forefront in CAR T-cell immunotherapy, well combines with the highly promising efficacy and safety data on CD44v6 CAR-T recently presented at the annual meeting of the American Society of Hematology: CAR-T therapies are demonstrating very encouraging features, thus attracting interest of many industrial players as well as public institutions. MolMed, with its proprietary CD44v6 CAR-T project and thanks to its widely-
recognized know how in cell and gene therapy manufacturing, is clearly well positioned to play a leading role in the breakthrough field of tumour immune-gene therapy, one of the fastest growing sectors of the innovative tumour therapies.”

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

**About MolMed**

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6, an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

**For further information:**

Laura Villa  
**Investor Relations & Communication Director**  
MolMed S.p.A.  
telefono: +39 02 21277.205  
fax: +39 02 21277.325  
e-mail: investor.relations@molmed.com

Press agent  
Federico Ferrari  
SEC Relazioni Pubbliche e Istituzionali s.r.l.  
phone: +39 02 6249991 – mobile +39 347 6456873  
e-mail: ferrari@secrp.it

**DISCLAIMER**

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking
statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A..